Cited by 877Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

2013 ETA Guideline: Management of Subclinical Hypothyroidism

Open access
Pearce, Simon H.S., Brabant, Georg, Duntas, Leonidas H., Monzani, Fabio, Peeters, Robin P., Razvi, Salman, Wemeau, Jean-Louis·2013·European Thyroid Journal

Abstract

Subclinical hypothyroidism (SCH) should be considered in two categories according to the elevation in serum thyroid-stimulating hormone (TSH) level: mildly increased TSH levels (4.0-10.0 mU/l) and more severely increased TSH value (>10 mU/l). An initially raised serum TSH, with FT4 within reference range, should be investigated with a repeat measurement of both serum TSH and FT4, along with thyroid peroxidase antibodies, preferably after a 2- to 3-month interval. Even in the absence of symptoms, replacement therapy with L-thyroxine is recommended for younger patients (<65-70 years) with serum TSH >10 mU/l. In younger SCH patients (serum TSH <10 mU/l) with symptoms suggestive of hypothyroidism, a trial of L-thyroxine replacement therapy should be considered. For such patients who have been started on L-thyroxine for symptoms attributed to SCH, response to treatment should be reviewed 3 or 4 months after a serum TSH within reference range is reached. If there is no improvement in symptoms, L-thyroxine therapy should generally be stopped. Age-specific local reference ranges for serum TSH should be considered in order to establish a diagnosis of SCH in older people. The oldest old subjects (>80-85 years) with elevated serum TSH ≤10 mU/l should be carefully followed with a wait-and-see strategy, generally avoiding hormonal treatment. If the decision is to treat SCH, then oral L-thyroxine, administered daily, is the treatment of choice. The serum TSH should be re-checked 2 months after starting L-thyroxine therapy, and dosage adjustments made accordingly. The aim for most adults should be to reach a stable serum TSH in the lower half of the reference range (0.4-2.5 mU/l). Once patients with SCH are commenced on L-thyroxine treatment, then serum TSH should be monitored at least annually thereafter.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000356507

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The optimal daily dose in overt hypothyroidism is 1.5-1.8 μg per kg of bodyweight, rounded to the nearest 25 μg.

    “The optimal daily dose in overt hypothyroidism is 1•5-1•8 μg per kg of bodyweight, 107,142,144 rounded to the nearest 25 μg.”

    From Hypothyroidism (2024) · cites this paper as [142]

    The Recommendations (p. 10) advise approximately 1.5 μg/kg/day of L-thyroxine for patients without cardiac disease who are being treated for subclinical hypothyroidism. They do not give a 1.5–1.8 μg/kg/day range for overt hypothyroidism or instruct rounding to the nearest 25 μg. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Up to 10% of treated diagnosed hypothyroid individuals report impaired quality of life despite achieving serum free thyroxine and thyroid stimulating hormone (TSH) levels within the laboratory reference range.

    “It is reported that up to 10% of treated diagnosed hypothyroid individuals report impaired quality of life, despite achieving serum free thyroxine and thyroid stimulating hormone (TSH) levels within the laboratory reference range”

    From Natural desiccated thyroid for the treatment of hypothyroidism? (2024) · cites this paper as [5]

    In “How to Treat?” (p. 10), the guideline says some treated patients with subclinical hypothyroidism have no improvement in symptoms and recommends adjusting treatment to bring TSH into the reference range. It does not report that up to 10% have impaired quality of life despite both free thyroxine and TSH being within laboratory reference ranges. (LLM, conf=0.79)

    Experimental — accuracy not yet measured
  • L-T4 monotherapy is the standard treatment for primary hypothyroidism, central hypothyroidism, and subclinical hypothyroidism patients candidate for replacement.

    “L-thyroxine (L-T4) monotherapy is the standard treatment for PH (4–6) and CH (4, 5, 7), and SCH patients candidate for replacement (4, 5, 8).”
  • Current clinical guidelines propose that thyroid hormone replacement therapy should not be routinely offered for adults with subclinical hypothyroidism.

    “which is supported by current clinical guidelines proposing that thyroid hormone replacement therapy should not be routinely offered for adults with subclinical hypothyroidism.12,13,14”
  • Current clinical guidelines from the American Thyroid Association and European Thyroid Association do not recommend treating subclinical hypothyroidism when TSH is 10 mIU/L or less (and without symptoms in younger individuals).

    “Current clinical guidelines from the American Thyroid Association14 and European Thyroid Association13 do not recommend treating subclinical hypothyroidism when TSH is 10 mIU/L or less (and without symptoms in younger individuals).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L.
Affiliations
  • Royal Victoria Infirmary (GB)
  • University Hospital Schleswig-Holstein (DE)
  • National and Kapodistrian University of Athens (GR)
  • University of Pisa (IT)
  • Erasmus MC (NL)
  • Queen Elizabeth Hospital (GB)
  • 8 Clinique Endocrinologique Marc Linquette, CHU, Lille, France
Venue
European Thyroid Journal
Published
2013-11-26
Volume
2
Issue
4
Pages
215-228
ISSN
  • 2235-0640 (ISSN-L)
  • 2235-0802
OpenAlex
W2149958970
Cited by
877
References
144
Citations by year
2026: 75 · 2025: 61 · 2024: 79 · 2023: 71 · 2022: 86 · 2021: 94 · 2020: 93 · 2019: 81 · 2018: 77 · 2017: 64 · 2016: 36 · 2015: 39 · 2014: 20
FWCI
24.91
Type
journal article
Language
en
Open access
Locations
  • European Thyroid Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
subclinical hypothyroidism, thyroid-stimulating hormone, thyroid peroxidase antibodies, wait-and-see strategy, older adults, treatment response monitoring, dose adjustment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review